Silexion Doses First Patient in Phase 2/3 Pancreatic Cancer Trial
SLXN sits 18% above its 52-week low of $0.236 on elevated volume (26× avg).
Summary
Silexion has dosed the first patient in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer, marking the transition from preclinical to active clinical execution. The trial will enroll approximately 18 patients in a safety run-in followed by 166 in a randomized cohort, with the first patient treated at Tel Aviv Sourasky Medical Center. This milestone is significant for a company with a market cap around $3.5 million and ongoing Nasdaq listing challenges, as it demonstrates operational progress despite financial constraints. The dual-route delivery approach—direct intratumoral injection plus subcutaneous dosing—addresses a key barrier in pancreatic cancer treatment. Investors will watch for preliminary clinical readouts, which management expects in the near term, though no specific date is provided.
Updates
· SEC 8-K — The 8-K attaches the press release announcing the first patient dosed in the Phase 2/3 trial of SIL204.
At the time of this announcement, SLXN was trading at $0.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.24 to $42.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.